Intrauterine hormonal levonorgestrel-releasing system in women in perimenopause


Cite item

Full Text

Abstract

We review the literature data devoted to use of the intrauterine levonorgestrel-releasing system (LNG-IUS), an effective method of prevention of unwanted pregnancies in women of reproductive age and fertile perimenopausal women with ovulatory menstrual cycles. It is also possible the use of LNG-IUS as ultra low dose hormone progestin component of hormone replacement therapy (HRT) with estrogens. The selection criteria for the use of LNG-IUD in premenopausal women as the progestin component of HRT are the presence of symptoms of climacteric syndrome, anovulation, and oligomenorrhea. The use of LNG-IUD in patients with hyperplastic processes of endometrium and breast, as well as dysmenorrhea, premenstrual syndrome, menorrhagia, endometriosis, premenstrual syndrome, anemia is most reasonable.

References

  1. Прилепская В.Н. Руководство по контрацепции. М.: Медпресс-информ, 2006.
  2. Григорьева В.А., Айламазян Э.К., Тарасова М.А. и др. Гинекологическая эндокринология. 2004. 6 (5).
  3. Зайдиева Я.З. Гормонопрофилактика и коррекция системных нарушений у женщин в перименопаузе. Автореф. дисс. докт. мед. наук. М., 1997.
  4. Кулаков В.И., Вихляева Е.М. Менопаузальный синдром (клиника, диагностика, профилактика и заместительная гормональная терапия). М., 1996.
  5. Прилепская В.Н. Контрацепция в различные возрастные периоды жизни женщины. М., 1998. С. 30-53.
  6. Прилепская В.Н., Меживитинова Е.А., Тагиева А.В. Внутриматочная контрацепция. М, 2000.
  7. Острейкова Л.И. Клинические аспекты применения внутриматочной левоноргестрел-рилизинг системы у женщин в пременопаузе. Автореф.канд. мед. наук. М.,2002
  8. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynecol 1990; 97(8): 690-4.
  9. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49(1): 56-72.
  10. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106(4): 813-7.
  11. Barbosa I, Bakos O, Olsson S et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42(1): 51-66.
  12. Barrington J, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104(5): 614-6.
  13. Chavez NF, Stewart EA.Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001; 44(2): 372-84.
  14. Coleman M, Cowan L, Farquhar C. The Levonorgestrel-Releasing Intrauterine Device: A Wider Role Than Contraception. Aust NZ Obstet Gynaecol 1997; 37 (2): 195-201.
  15. Critchley H, Wang H, Kelly R et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998; 13(5): 1210-710.
  16. Crook D, Cust M, Gangar K et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950-5.
  17. Crosignani P, Vercellini P, Mosconi P et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257-63.
  18. Faundes A, Alvarez F, Brache V, Tejada A. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gyneacol Obstet 1988; 26: 429-33.
  19. Greendale G, Lee N, Arriola E. The menopause. Lancet 1999; 353(9152): 571-80.
  20. Heikkila M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982; 25(3): 279-92.
  21. Hurk P, O'Brien S. Non-contraceptive use of the levonorgestrel-releasing intrauterine system. Obstet Gynaecol 1999; 1(1): 13-9.
  22. Irvine G, Campbell-Brown M, Lumsden M et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105(6): 592-8.
  23. Johansson E. Future aspects of the levonorgestrel-releasing intrayterine systetem. Gynecoly Forum 1998; 3(3): 311-32.
  24. Jonsson B, Landgren B, Enezoth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991; 43: 447-58.
  25. Klein N, Soules M. Endocrine changes of the perimenopause. Clin Obstet Gynecol 1998; 41(4): 912-20.
  26. Kubba A. Contraception: a review. Int J Clin Pract 1998; 52(2): 102-5.
  27. Lahteenmaki P. Health benefits of a levonorgestrel-releasing IUD (abstract). 7th European Congress of Gynaecology and Obstetric, 1992, 28 June - 1 July, Helsinki, Finland.
  28. Lahteenmaki P, Bardin C, Eloma K et al. Selection and performance of the levonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand 1997; 164: 69-74.
  29. Luukkainen T, Allonen H, Haukkamaa M et al. Five years' experience with levonorgestrel-releasing IUDs. Contraception 1986; 33(2): 139-48.
  30. Mandelin E, Koistinen H, Koistinen R. et al. Levonorgestrel-releasind intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Hum Reprod 1997; 12(12): 2671-5.
  31. Hampton NR, Rees MC et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005, 20(9): 2653-60.
  32. Nilsson C, Lahteenmaki P, Luukkainen T. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device. Contraception 1980; 21: 155-64.
  33. Pakarinen P, Lahteenmaki P, Rutanen E. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstet Gynaecol Scand 1999; 78 (5): 423-8.
  34. Pekonen F, Nyman R, Lahteenmaki P et al. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992; 75(2): 660-4.
  35. Petta C. A. et al. Hum Reprod 2005; 5 (3): 1-6.
  36. Rutanen E. Endometrial response to intrauterine release of levonorgestrel Gynaecol Forum 1998; 3(3): 11-3.
  37. Rybo G. Tretment of menorrhagia using intrauterine administration of levonorgestrel Gynecol Forum 1998; 3(3): 20-2.
  38. Scholten P, Eykeren M, Christiaens G et al. Menstrual blood loss with levonorgestrel Nova-T and multiload Cu 250 intrauterine devices (thesis), Utrecht: University Hospital 1989; 35-45.
  39. Steinberg K, Thacker S, Smith J et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1990; 265: 1985-90.
  40. Stewart A et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG: an international Journal of Obstetrics & Gynecology, 2001; 108: 74-86.
  41. Stovall TG, Ling FW, Henry LC et al A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420-3.
  42. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2488&mid=1085056570&magid=185&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies